Previous Article | Next Article 
Infection and Immunity, April 1999, p. 1821-1827, Vol. 67, No. 4
0019-9567/99/$04.00+0
Copyright © 1999, American Society for Microbiology. All rights reserved.
Antibodies Reactive with the N-Terminal Domain of
Plasmodium falciparum Serine Repeat Antigen Inhibit Cell
Proliferation by Agglutinating Merozoites and Schizonts
Xin-Li
Pang,
Toshihide
Mitamura, and
Toshihiro
Horii*
Department of Molecular Protozoology,
Research Institute for Microbial Diseases, Osaka University, Suita
Osaka 565-0871, Japan
Received 29 September 1998/Returned for modification 29 October
1998/Accepted 5 January 1999
 |
ABSTRACT |
The serine repeat antigen (SERA) is a vaccine candidate antigen of
Plasmodium falciparum. Immunization of mice with
Escherichia coli-produced recombinant protein of the SERA
N-terminal domain (SE47') induced an antiserum that was inhibitory to
parasite growth in vitro. Affinity-purified mouse antibodies specific
to the recombinant protein inhibited parasite growth between the
schizont and ring stages but not between the ring and schizont stages.
When Percoll-purified schizonts were cultured with the
affinity-purified SE47'-specific antibodies, schizonts and merozoites
were agglutinated. Indirect-immunofluorescence assays with unfixed
parasite cells showed that SE47'-specific immunoglobulin G (IgG) bound
to SERA molecules on rupturing schizonts and merozoites but the IgG did
not react with the schizont-infected erythrocytes (RBC). Furthermore,
double-fluorescence staining against SE47'-specific IgG and anti-human
RBC membrane IgG showed that the RBC membrane disappeared from
SE47'-specific-IgG-bound schizonts after cultivation. These
observations suggest that the SE47'-specific antibodies inhibit
parasite growth by cross-linking SERA molecules that are associated
with merozoites in rupturing schizonts with partly broken RBC and
parasitophorous vacuole membranes, blocking merozoite release.
 |
INTRODUCTION |
Malaria remains one of the most
devastating human infectious diseases. The appearance of malaria
parasites with resistance to antimalarial drugs and of mosquito vectors
with resistance to insecticides has made it more difficult to cure and
prevent malaria infection, respectively. It is therefore of increasing importance to develop malaria vaccines.
The Plasmodium falciparum serine repeat antigen (SERA) is
one of the malaria vaccine candidate antigens against the asexual blood
stage (for reviews, see references 1 and
18). SERA, also known as SERP (17) and
pl26 (6, 7) is an asexual blood stage antigen produced in
large amounts specifically during late trophozoite and schizont stages
(2, 5). SERA was originally identified by a mouse monoclonal
antibody (immunoglobulin M [IgM]) that inhibits parasite growth in
vitro (2, 13). Immunization of Aotus and squirrel monkeys
with a recombinant protein comprising part or all of the N-terminal
domain (47 kDa) of SERA conferred significant protection from challenge
infection (14-16, 27).
SERA protein (from the Honduras-1 strain of P. falciparum)
contains 989 amino acids, including a repetition of 35 serine residues (5), and has limited sequence homology with the active site of serine proteases (9, 12). However, the physiological
function of SERA is poorly characterized. Comparison of the sequences
of several allelic forms of SERA showed limited diversity in the N-terminal region, and the majority of the diversity is due to deletion
or insertion events rather than point mutations (22). The
recent analysis of the P. falciparum chromosome 2 genome
sequence revealed that the SERA gene and seven SERA gene homologues are clustered (11).
The SERA polypeptide is secreted primarily into the lumen of the
parasitophorous vacuole after removal of its 22-amino-acid signal
peptide (6). Coincident with the release of merozoites, a
large fraction of the total pool of the 126-kDa SERA protein is
proteolytically processed into a 47-kDa N-terminal domain, a 50-kDa
central domain, an 18-kDa C-terminal domain, and a poorly characterized
6-kDa domain (8). There are conflicting reports arguing the
presence or absence of SERA on the merozoite surface (2,
25). SERA has recently been identified as a phospholipid-binding protein that can recognize inner-leaflet phospholipids of the host
erythrocytes (RBC) (25).
Vaccination of rodents or goats with recombinant SERA N-terminal-domain
protein elicits antibodies that inhibit the growth of the parasite in
vitro (3, 4, 10, 24, 26). It is therefore of great interest
to elucidate the mechanism of inhibition of the parasite's
proliferation by anti-SERA antibodies. In this report, we examine the
effect of the affinity-purified SE47'-specific IgG on the parasite's
development in RBC. The results demonstrate that the SE47'-specific IgG
inhibited parasite growth by a mechanism involving agglutination of
merozoites and rupturing of schizonts.
 |
MATERIALS AND METHODS |
Protein expression and purification.
The recombinant SE47'
protein (amino acids 17 to 382) was expressed in XL1-Blue cells by
using a synthetic SERA gene and was purified according to the method of
Sugiyama et al. (26) and Barr et al. (3).
Briefly, 10 g of Escherichia coli cells containing induced SE47' protein was suspended in STE buffer (50 mM Tris-HCl [pH
8.0]-5 mM EDTA-25% sucrose-5 mM 2-mercaptoethanol) with 0.1 mg of
lysozyme ml
1 and sonicated. After centrifugation,
ammonium sulfate was added to the supernatant at a final 30%
saturation to precipitate the SE47' protein. The precipitate was
collected by centrifugation and dissolved in TEGB buffer (10 mM
Tris-HCl [pH 7.6]-1 mM EDTA-10% glycerol-10 mM 2-mercaptoethanol)
containing 8 M urea and 0.1% sodium dodecyl sulfate (SDS). The
solution was dialyzed against phosphate-buffered saline (PBS) (10 mM
NaH2PO4, 10 mM Na2HPO4, 100 mM NaCl, pH 6.8) containing 0.1% SDS and was then subjected to gel
filtration on TSK gel G 4000 SW (Tosoh, Tokyo, Japan). The
chromatography was carried out at a flow rate of 1 ml/min, and 0.5-ml
fractions were collected. Fractions 34 and 35, which contained SE47'
protein, were pooled and mixed with 100 mM 2-mercaptoethanol. The
pooled fraction was then heated at 80°C for 15 min and subjected to
the same column chromatography. The SE47' protein that was recovered in
fractions 39 and 40 was concentrated by a membrane filter unit,
Centriprep 10 (Amicon). The preparations yielded 15 mg of SE47'
protein. The protein was dialyzed against PBS (1.9 mM
NaH2PO4, 8.1 mM
Na2HPO4, 154 mM NaCl, pH 7.2) containing 0.1% SDS and kept at
20°C.
Immunization of mice.
Mice (6-week-old female BALB/c; Japan
SLC Inc.) were immunized with SE47' and Freund's adjuvant (Difco) by
subcutaneous injection on days 0, 14, and 28. Each mouse received 50 µg of the protein at the initial injection followed by 25 µg of the
protein at the second and third injections. The SE47' protein was
emulsified at a 1:1 ratio with Freund's complete adjuvant for the
initial injection and with Freund's incomplete adjuvant for the second and third injections. For control serum, five mice were immunized with
PBS containing 0.1% SDS by the procedures described above. On day 35, blood was collected in fresh Eppendorf tubes and incubated at 37°C
for 1 h, followed by 12 h at 4°C. The sera were then
separated by centrifugation at 1,250 × g for 10 min. All
sera were heat inactivated at 56°C for 30 min and stored in aliquots
at
20°C.
ELISA and Western blot analyses.
Enzyme-linked immunosorbent
assay (ELISA) was performed as described previously (24,
26). One microgram of SE47' protein was used to coat each well of
a 96-well MaxiSorp dish (Nunc). SE47'-specific IgG in a serum was
detected with biotinylated horse IgG specific to mouse IgG (Vector
Laboratories) as a secondary antibody. Avidin-conjugated peroxidase
(ABC kit; Vector Laboratories) and
2,2'-azino-bis-(3-ethylbenzothiazoline-6-sulfonic acid) were used for
ELISA. The ELISA titer was determined by a cutoff absorbance of 0.2 at
405 nm with a microtiter plate reader (Titertek Multiskan MCC/340
MKII). The purified recombinant SE47' protein and a cell homogenate of
P. falciparum (FCR3) (24) were used for the
Western blot analyses (26). Affinity-purified SE47'-specific
IgG and biotinylated horse IgG specific to mouse IgG were used as
primary and secondary antibodies, respectively. Avidin-conjugated
peroxidase and diaminobenzidine tetrahydrochloride were used for the
Western blot analysis.
Preparation of IgG.
Total IgG from mouse serum was prepared
on a Hi-Trap protein A-Sepharose column (Pharmacia). Pooled anti-SE47'
serum (10 ml) or pooled control serum (2.0 ml) was diluted 10-fold with
PBS (1.4 mM KH2PO4, 4.3 mM
Na2HPO4, 2.7 mM KCl, 137 mM NaCl, pH 8.0) and
applied to the column (bed volume, 5 and 1 ml, respectively). Total IgG
was eluted from the column with 0.1 M citrate buffer (pH 2.5). The
concentration of IgG was determined by measuring optical density at 280 nm (an absorbance of 1.4 is equivalent to 1.0 mg of IgG
ml
1). SE47'-specific IgG was prepared from total IgG by
affinity chromatography with Sepharose 4B (Pharmacia) covalently linked with SE47' protein. The bound IgG was eluted with 0.1 M glycine-HCl (pH
2.5) and was immediately neutralized with 1/10 volume of 1 M Tris-HCl
(pH 8). The eluted fractions were extensively dialyzed against PBS (1.4 mM KH2PO4, 4.3 mM
Na2HPO4, 2.7 mM KCl, 137 mM NaCl, pH 8.0) and
then dialyzed against a basal medium (RPMI 1640) for the parasite
culture. The SE47'-specific IgG was concentrated by Centriprep 10 to 3 mg ml
1 and stored at
20°C. In a typical preparation,
1.5 mg of SE47'-specific IgG was obtained from 4 mg of total IgG that
was prepared from 1 ml of antiserum. Nonspecific IgG was prepared from
control mouse serum with a Hi-Trap protein A-Sepharose column
(Pharmacia) as described above. When the nonspecific IgG was applied to
this SE47' affinity column, the adsorbed IgG was undetectable.
Parasite cell preparation.
P. falciparum FCR3 was
maintained in culture according to the methods of Trager and Jensen
(29) and Sugiyama et al. (26). The parasites were
grown in a 5% O2 and 5% CO2 atmosphere with 2% (vol/vol) type O RBC in a culture medium containing 10%
heat-inactivated human type O serum. Synchronization of parasite growth
was done by two consecutive D-sorbitol treatments (5%)
with a 30-h interval (30). This method produced early ring
stage parasites with a 2- to 6-h window of age span after invasion. RBC
infected by late trophozoites and schizonts were isolated by 63%
(vol/vol) Percoll (Pharmacia) density centrifugation from a
synchronized culture as described by Tosta et al. (28).
Free merozoites were isolated as follows. Percoll-purified RBC infected
by trophozoites and schizonts were cultured in complete medium without
fresh RBC. After 3 h of cultivation, the culture was centrifuged
at 200 × g for 3 min. The supernatant was filtered through 2-µm-pore-size membrane sieves (prefilter) (Millipore) according to the method of Mrema et al. (23) and was
immediately used for further experiments. The free merozoites were
visualized by Giemsa staining.
Growth inhibition and invasion assay.
Parasite growth
inhibition assays were performed in a medium containing 2% RBC with a
0.5% initial parasitemia in the presence of the indicated mouse IgG or
serum for 24 or 72 h in a 96-well microtiter plate. The culture
medium was replaced every 24 h with fresh medium with or without
the indicated IgG. Parasite growth was examined by Giemsa staining of
thin smears, and the parasitemia was scored by counting over 5,000 RBC
in a slide. The observed parasitemia was divided by the parasitemia of
the indicated control culture to give the percent growth inhibition.
Assay for parasite cell agglutination.
Percoll-purified RBC
infected by trophozoites and schizonts were cultured in microculture
plates (100 µl per well) in the presence of the indicated IgG at a
density of 105 schizonts ml
1 without fresh
RBC. After cultivation for the indicated time, all of the culture was
smeared on a glass slide and Giemsa stained. Mature schizonts,
agglutinated merozoites, and single merozoites were counted over all
areas of the smear.
Purified merozoites (10
5) were incubated in 100 µl of
complete medium containing 100 µg of the indicated mouse IgG
ml
1 without fresh RBC at 37°C for 30 min. The
agglutinated merozoites
and free merozoites were counted in
Giemsa-stained thin smears
as described
above.
Immunofluorescence assay.
Percoll-purified RBC infected by
trophozoites and schizonts were cultured for 0, 4, or 8 h at a
density of 106 ml
1 in a complete medium
containing 100 µg of the indicated IgG ml
1 at 37°C.
After cultivation, the parasite cells were washed three times by
centrifugation at 1,000 × g for 3 min and were
subjected to immunofluorescence assays. The cells were resuspended in
100 µl of PBS-3% bovine serum albumin (BSA) containing fluorescein isothiocyanate (FITC)-conjugated goat IgG against mouse IgG (ICN Pharmaceuticals, Inc.-Cappel Products) diluted 1:1,000 and 1 µg of
diamidinophenylindole (DAPI) (catalog no. D-1388; Sigma)
ml
1. After incubation for 30 min at 37°C, the parasite
cells were washed five times with PBS and fixed in PBS containing 3%
paraformaldehyde. The fixed cells were mounted with PermaFluor aqueous
mounting medium (Immunon) and inspected by fluorescence microscopy
(Axioskop; Zeiss). For the double-fluorescence assay, Percoll-purified
trophozoites and schizonts were cultured in a complete medium
containing the indicated IgG and washed as described above. The cells
were then incubated in PBS-3% BSA containing rabbit IgG against human
RBC membrane (ICN Pharmaceuticals, Inc.-Cappel Products) diluted
1:5,000 at 37°C for 30 min. After being washed three times with PBS,
the cells were resuspended in PBS-3% BSA containing FITC-conjugated goat IgG against mouse IgG, 1 µg of DAPI ml
1, and
FluoroLinkCy3-labeled goat IgG against rabbit IgG (Amersham) diluted
1:1,000. The parasite cells were washed and mounted for fluorescence
assay as described above.
Merozoites were fixed immediately after purification with 2%
paraformaldehyde in PBS on ice for 30 min and spread on a slide.
After
being air dried, the slides were incubated for 30 min at
37°C in
PBS-3% BSA and subsequently reacted with the SE47'-specific
IgG in
PBS-3% BSA. The slides were washed three times in PBS and
then
incubated with secondary antibody (FITC-conjugated goat IgG
against
mouse IgG) in PBS containing 1 µg of DAPI ml
1 to stain
the parasite nuclei. The slides were washed five times
in PBS, mounted,
and inspected as described
above.
 |
RESULTS |
SE47'-specific IgG inhibits P. falciparum growth.
The antiserum from mice immunized with recombinant SE47' protein was
prepared as described in Materials and Methods. The ELISA titer of
anti-SE47' serum was 87,000, while that of the control serum was <50.
The parasite growth inhibition assay was carried out with 5% (vol/vol)
anti-SE47' serum. After incubation for 72 h, the parasitemia was
2%, while the parasitemias in the media with the control serum and
without serum were 7.2 and 9.1%, respectively. To verify that parasite
growth is inhibited by IgG specific to SE47' protein in the prepared
antiserum, we purified total and SE47'-specific IgG from mouse
antiserum with protein A and Sepharose 4B covalently cross-linked with
recombinant SE47' protein. The cross-reactivity of the purified
SE47'-specific IgG to both the parasite SERA protein and recombinant
SE47' protein was confirmed by Western blot analysis (Fig.
1). The total IgG and the SE47'-specific IgG were subjected to the parasite growth inhibition assay. Parasite growth was inhibited by both total IgG and SE47'-specific IgG in a
concentration-dependent manner (Fig. 2).
Maximum inhibition (80%) was obtained with the SE47'-specific IgG at
100 µg ml
1 after cultivation for 72 h; however,
further inhibition was not observed with increasing concentrations of
the IgG.

View larger version (42K):
[in this window]
[in a new window]
|
FIG. 1.
Western blot of P. falciparum cell homogenate
and recombinant SE47' protein with affinity-purified SE47'-specific
IgG. The purified recombinant SE47' protein (lanes 1 and 2) and
Percoll-purified trophozoites and schizonts, 105 cells of
P. falciparum FCR3 (lanes 3 and 4), were run in 6 to 12%
gradient SDS-polyacrylamide gels under nonreducing conditions. The
arrow indicates the gel top. Western blotting was performed with
SE47'-specific IgG (lanes 1 and 3) or nonspecific IgG (lanes 2 and
4).
|
|

View larger version (17K):
[in this window]
[in a new window]
|
FIG. 2.
P. falciparum parasite growth inhibition by
mouse IgG specific to SE47'. Cells of P. falciparum FCR3 at
late trophozoite and schizont stages were cultured for 72 h with
or without mouse IgG. Total IgG (solid circles) and SE47'-specific IgG
(open circles) were prepared from anti-SE47' mouse antisera as
described in Materials and Methods. The initial parasitemia was 0.5%.
The parasitemia of the control culture with nonspecific IgG (200 µg
ml 1) or without IgG after 72 h of cultivation was
5.42 or 5.61%, respectively. Percent growth inhibition (shown as
means ± standard deviations; n = 4) was
calculated by using the parasitemia of the culture grown with
nonspecific IgG.
|
|
SE47'-specific IgG inhibits P. falciparum development
from schizont to ring.
To determine the parasite developmental
stage where the primary inhibition by SE47'-specific IgG occurs, the
parasite cells were synchronized. Synchronized ring or trophozoite and
schizont stage parasites were grown for 24 h in the presence of
SE47'-specific IgG or nonspecific IgG or without IgG. All ring stage
parasites developed to trophozoites and schizonts in the presence of
SE47'-specific IgG (Fig. 3A). In
contrast, initially inoculated trophozoites and schizonts (0.5%
parasitemia) developed to 0.54% rings and 0.21% schizonts in the
presence of SE47'-specific IgG while trophozoites and schizonts
developed to 2.5% parasitemia of rings and 0% parasitemia of
trophozoites and schizonts in the presence of nonspecific IgG or no IgG
(Fig. 3B). These results indicate that SE47'-specific IgG inhibits
parasite development from the schizont stage to the ring stage but
not the intracellular development of the parasite from ring stage to
schizont stage.

View larger version (26K):
[in this window]
[in a new window]
|
FIG. 3.
Stage specificity of the inhibitory effect of the
SE47'-specific IgG on P. falciparum growth. Synchronized
P. falciparum FCR3 cells were cultured for 24 h in the
presence of 100 µg of SE47'-specific IgG (bars 1) or nonspecific IgG
(bars 2) ml 1 or without IgG (bars 3). (A) Initial
parasitemia was 0.5% at ring stage. (B) Initial parasitemia was 0.5%
at late trophozoite and schizont stages. Both the results for
intraerythrocyte growth and those for invasion are given as the mean
percentage of parasitemia with a standard error (mean ± standard
deviation; n = 3).
|
|
When Percoll-purified trophozoites and schizonts were cultured with
various concentrations of SE47'-specific IgG for 24 h,
development
to the ring stage was inhibited as a function of the
antibody
concentration up to 100 µg ml
1 (Fig.
4). The maximum inhibition observed was
60% in one cycle
of parasite cell proliferation. This observation was
similar to
the result shown in Fig.
2 and further substantiated the
inhibitory
effect of SE47'-specific IgG on parasite development from
schizonts
to rings.

View larger version (13K):
[in this window]
[in a new window]
|
FIG. 4.
P. falciparum parasite invasion inhibition by
mouse IgG specific to SE47'. The growth inhibition assay was carried
out with Percoll-purified trophozoite and schizont parasite cells in
medium containing the indicated concentrations of SE47'-specific IgG
(circles) or nonspecific IgG (squares). The initial parasitemia was
0.5%. The parasitemias were counted after 24 h on each culture
(shown as means ± standard deviations; n = 3).
|
|
SE47'-specific IgG agglutinates schizonts and merozoites.
The
effect of SE47'-specific IgG on parasite cell development was further
analyzed by using purified RBC infected by trophozoites and schizonts.
Percoll-purified parasite cells the majority of which were schizonts
(90% schizonts and 10% late trophozoites) were cultured with
SE47'-specific or nonspecific IgG in the absence of fresh RBC. After 4 and 8 h of incubation with SE47'-specific IgG, agglutinated
schizonts and agglutinated merozoites were observed by Giemsa staining
(Fig. 5B and C). In a control culture
with nonspecific IgG, predominantly single rupturing schizonts and single merozoites were observed (Fig. 5F and G). To examine whether merozoites were agglutinated with SE47'-specific IgG, isolated merozoites were incubated with each IgG. The merozoites were
agglutinated by SE47'-specific IgG but not by nonspecific IgG, as shown
in Fig. 5D and H. The presence of SERA on merozoites was confirmed by
FITC assay (see Fig. 7, row 5).

View larger version (61K):
[in this window]
[in a new window]
|
FIG. 5.
SE47'-specific-IgG-mediated parasite cell agglutination.
Percoll-purified trophozoites and schizonts were cultured at 37°C in
a medium containing 100 µg of SE47'-specific IgG (A, B, and C) or
nonspecific IgG (E, F, and G) ml 1. After incubation for 0 (A and E), 4 (B and F), and 8 (C and G) h, the parasite cells were
Giemsa stained. Merozoites were isolated as described in Materials and
Methods. Soon after isolation, the merozoites were incubated with 100 µg of SE47'-specific IgG (D) or nonspecific IgG (H) ml 1
at 37°C for 30 min and Giemsa-stained.
|
|
For quantitative analysis, total single and agglutinated merozoites and
schizonts were counted. In a culture with nonspecific
IgG, the number
of single merozoites increased and that of schizonts
decreased with
cultivation time (Fig.
6A and C). In
contrast,
the number of single merozoites decreased and that of
agglutinated
merozoites increased in the presence of SE47'-specific IgG
(Fig.
6A and B). The number of schizonts remaining after 10 h of
cultivation
was higher in SE47'-specific IgG than in nonspecific IgG
(Fig.
6C). These results indicate that SE47'-specific IgG agglutinates
both merozoites and schizonts, causing depletion of single merozoites.
The decrease of single merozoites was quantitatively correlated
with
parasite growth inhibition (Fig.
3).

View larger version (17K):
[in this window]
[in a new window]
|
FIG. 6.
Number of agglutinated parasite cells with
SE47'-specific IgG. Percoll-purified trophozoites and schizonts
(104) were cultured with nonspecific IgG (squares) or
SE47'-specific IgG (circles) for 0 to 10 h in 100 µl of medium.
The total numbers of single merozoites (A), agglutinated merozoites
(B), and schizonts (C) in the cultures are shown (means ± standard deviations; n = 3).
|
|
Localization of SE47'-specific IgG in agglutinated parasite
cells.
To examine whether SE47'-specific IgG was present in the
agglutinated parasite cells, Percoll-purified RBC infected by
trophozoites and schizonts were cultivated with SE47'-specific IgG for
4 and 8 h and then reacted with FITC-conjugated goat IgG against
mouse IgG. The FITC assay was carried out without fixation of the
parasite cells to observe the distribution of SE47'-specific IgG under physiological conditions. Both agglutinated schizonts and merozoites were strongly fluorescent in a FITC assay (Fig.
7). The results showed that
SE47'-specific IgG was present in the agglutinated parasite cells. When
freshly prepared schizonts were subjected to FITC assay without
fixation, fluorescence was not observed. Schizonts permeated by
paraformaldehyde fixation, however, were fluorescent (Fig. 7). These
results were consistent with previous observations that SERA molecules
are not on the infected RBC membrane but are predominantly in the
parasitophorous vacuole (7, 17).

View larger version (50K):
[in this window]
[in a new window]
|
FIG. 7.
Agglutinated parasite cells are surrounded by
SE47'-specific IgG. Percoll-purified trophozoites and schizonts were
cultured with 100 µg of SE47'-specific IgG ml 1 for 4 and 8 h, and the parasite cells were washed and stained with
FITC-conjugated goat anti-mouse IgG. Rows: 1, agglutinated schizonts
after 4 h of cultivation; 2, agglutinated merozoites after 8 h of cultivation; 3, freshly purified single schizonts; 4, freshly
purified single schizonts after paraformaldehyde fixation; 5, isolated
merozoites. Nomarski, differential interference microscope image.
|
|
Under microscopic examination of the Giemsa-stained parasite cells,
freshly prepared schizonts appeared to be surrounded by
the RBC
membrane; however, schizonts cultured for 4 to 8 h appeared
to
have no RBC membrane (data not shown). If the rupturing schizonts
break
RBC membranes before the release of merozoites, anti-SERA
IgG can bind
SERA in the parasitophorous vacuole. Double-immunofluorescence
assays
were performed to investigate the presence of RBC membranes
surrounding
the agglutinated schizonts in the presence of SE47'-specific
IgG
without fixation. When Percoll-purified schizonts were immediately
subjected to double-immunofluorescence assay, Cy3 fluorescence
from
rabbit IgG against human RBC membrane was apparent. However,
FITC
fluorescence from SE47'-specific IgG against SERA was not
observed
(Fig.
8, column T = 0 h). After
cultivation with SE47'-specific
IgG for 4 h, a majority of
schizonts were agglutinated and both
Cy3 and FITC fluorescences were
observed (Fig.
8, column T = 4
h). An additional 4 h of
cultivation caused a disappearance of
Cy3 fluorescence but did not
effect FITC fluorescence (Fig.
8,
column T = 8 h).

View larger version (46K):
[in this window]
[in a new window]
|
FIG. 8.
Double-immunofluorescence staining of SE47'-specific IgG
and RBC membranes in schizonts. Percoll-purified trophozoites and
schizonts were cultured with 100 µg of SE47'-specific IgG
ml 1 for 0, 4, and 8 h, and the parasite cells were
washed and reacted with rabbit IgG against RBC membrane. Cy3- or
FITC-conjugated secondary antibodies were used to identify RBC
membranes (red fluorescence) and SE47'-specific IgG (green
fluorescence). Columns: T=0h, fresh schizonts before cultivation; T=4h,
agglutinated schizonts after 4 h of cultivation; T=8h,
agglutinated schizonts after 8 h of cultivation. Normarski,
differential interference microscope image.
|
|
 |
DISCUSSION |
In previous work, we found that affinity-purified SE47'-specific
mouse IgG inhibits P. falciparum growth in in vitro culture and that the growth inhibition was enhanced by active complement through the classical pathway (24). However, it was not
clear how antibodies against SERA inhibit parasite growth. In this
study, we demonstrate that SE47'-specific IgG inhibits parasite growth at a stage between schizont and ring. We also showed that
SE47'-specific IgG binds to the rupturing schizont, causing
agglutination of the parasite cells and thus preventing the release of
free merozoites. It is highly probable that the inhibition of
free-merozoite release by SE47'-specific IgG causes the parasite growth
inhibition, although the antibodies may also block the binding of
merozoites to RBC.
SERA molecules are not exposed to the outside of the RBC membranes of
schizont stage parasites immediately after isolation with Percoll. This
observation is consistent with previous reports that SERA primarily
localizes in the parasitophorous vacuole (7, 17). When
probed with anti-human RBC antibodies, the RBC membrane around
schizonts was dissociated during cultivation (Fig. 8). Although the
process of schizont rupture is not yet clear, single merozoites would
be released after breaking of both RBC and parasitophorous vacuole
membranes. SE47'-specific IgG could invade the parasitophorous vacuole
when both the RBC and parasitophorous membranes begin to rupture.
Since SERA molecules were observed by
immunoelectronmicroscope around each merozoite in a
schizont-infected RBC (23a), SE47'-specific IgG would
cross-link merozoites, preventing merozoite dispersal. Further
examination of rupturing schizonts is necessary to understand the
status of the host RBC membrane and the parasite vacuole membrane(s). Our proposed model for parasite growth inhibition is shown in Fig.
9.

View larger version (13K):
[in this window]
[in a new window]
|
FIG. 9.
Model for parasite growth inhibition by SE47'-specific
IgG. PVM, parasitophorus vacuole membrane.
|
|
Agglutinated schizonts were observed only when Percoll-purified
schizonts were cultivated with SE47'-specific IgG. In contrast, agglutinated schizonts were rarely found in the parasite cultures with
a 2 to 5% hematocrit. Under standard culture conditions, where
parasitemia is usually less than 5%, it is less probable for schizonts
to contact and agglutinate with each other. The parasite growth
inhibition by SE47'-specific IgG would therefore predominantly result
from cross-linking of merozoites in rupturing schizonts. We have no
substantial evidence to explain why excess antibody does not lead to
complete growth inhibition. It is possible that if a single merozoite
fully bound with SE47'-specific IgG still retains invasion capacity,
then complete growth inhibition may not be achieved with excess
antibodies. Although our data showed that SE47'-specific IgG
efficiently inhibited the production of free merozoites, further
mechanism studies are required to determine whether additional
mechanisms are responsible for the observed growth inhibition, for
example, whether antibody to SERA blocks merozoite invasion.
In this study, we present evidence that SE47'-specific IgG agglutinated
merozoites. In addition, SERA protein was also identified on the
surface of single merozoites (Fig. 7). However, we could not detect
SERA on the merozoite surface when filter-purified merozoites were
subsequently washed by low-speed centrifugation (data not shown). It
is, therefore, likely that SERA weakly associates with the merozoite,
unlike MSP-1, which is covalently bound to the merozoite membrane by
GPI anchor. SERA has no predicted membrane-spanning domain or GPI
anchor (5).
Miller et al. showed that the merozoites of Plasmodium
knowlesi agglutinate as they are released or agglutinate within
the RBC ghost in the presence of rhesus monkey immune serum
(21). Lyon et al. reported that when P. falciparum erythrocytic schizonts are incubated with
growth-inhibitory immune human serum, antibodies prevent dispersal of
merozoites and result in inhibition of parasite growth by formation of
immune complexes of merozoites (ICM) (19). The agglutinated
merozoites observed in this study are morphologically similar to the
structure of reported ICM. Since SERA protein was identified as one of
the antigens present in ICM (20), anti-SERA antibodies may
contribute to formation of ICM. Investigation of human anti-SERA IgG in
areas of endemicity would provide further insights into SERA vaccine development.
Understanding the effector mechanisms that prevent parasite
proliferation is highly important for the development of an effective malaria vaccine. The present study provides a molecular basis for a
mechanism of parasite growth inhibition by mouse anti-SERA N-terminal
domain IgG that primarily prevents merozoite dispersal. In addition,
anti-SERA N-terminal-domain IgG-bound parasite cells are killed by
complement as previously reported (24). It is therefore of
great importance for SERA-based malaria vaccine development to design
methods to induce anti-SERA antibodies that effectively cross-link merozoites.
 |
ACKNOWLEDGMENTS |
We are grateful to D. Bzik and K. Maeshima for discussion.
This work was supported by a Grant-in-Aid for Scientific Research on
Priority Areas (08281104) from the Ministry of Education, Science,
Sports and Culture of Japan.
 |
FOOTNOTES |
*
Corresponding author. Mailing address: Department of
Molecular Protozoology, Research Institute for Microbial Diseases,
Osaka University, Suita Osaka 565-0781, Japan. Phone: 81-6-6879-8280. Fax: 81- 6-6879-8281. E-mail:
horii{at}biken.osaka-u.ac.jp.
Editor:
J. M. Mansfield
 |
REFERENCES |
| 1.
|
Anders, R. F.
1997.
Vaccines against asexual blood stages of Plasmodium falciparum, p. 1035-1055.
In
M. M. Levine, G. C. Woodrow, J. B. Kaper, and G. S. Cobon (ed.), New generation vaccines, 2nd ed. Marcel Dekker, Inc., New York, N.Y.
|
| 2.
|
Banyal, H. S., and J. Inselburg.
1985.
Isolation and characterization of parasite-inhibitory Plasmodium falciparum monoclonal antibodies.
Am. J. Trop. Med. Hyg.
34:1055-1064.
|
| 3.
|
Barr, P. J.,
J. Inselburg,
K. M. Green,
J. Kansopon,
B. K. Hahm,
H. L. Gibson,
C. T. Lee-Ng,
D. J. Bzik,
W.-B. Li, and I. C. Bathurst.
1991.
Immunogenicity of recombinant Plasmodium falciparum SERA proteins in rodents.
Mol. Biochem. Parasitol.
45:159-170[Medline].
|
| 4.
|
Bathurst, I. C.,
H. L. Gibson,
J. Kansopon,
B. K. Hahm,
K. M. Green,
S. P. Chang,
G. S. N. Hui,
W. A. Siddiqui,
J. Inselburg,
P. Millet,
I. A. Quakyi,
D. C. Kaslow, and P. J. Barr.
1993.
An experimental vaccine cocktail for Plasmodium falciparum malaria.
Vaccine
11:449-456[Medline].
|
| 5.
|
Bzik, D. J.,
W.-B. Li,
T. Horii, and J. Inselburg.
1988.
Amino acid sequence of the serine-repeat antigen (SERA) of Plasmodium falciparum determined from cloned cDNA.
Mol. Biochem. Parasitol.
30:279-288[Medline].
|
| 6.
|
Debrabant, A.,
P. Maes,
P. Delplace,
J.-F. Dubremetz,
A. Tartar, and D. Camus.
1992.
Intramolecular mapping of Plasmodium falciparum p126 proteolytic fragments by N-terminal amino acid sequencing.
Mol. Biochem. Parasitol.
53:89-96[Medline].
|
| 7.
|
Delplace, P.,
B. Fortier,
G. Tronchin,
J.-F. Dubremetz, and A. Vernes.
1987.
Localization, biosynthesis, processing and isolation of a major 126 kDa antigen of the parasitophorous vacuole of Plasmodium falciparum.
Mol. Biochem. Parasitol.
23:193-201[Medline].
|
| 8.
|
Delplace, P.,
A. Bhatia,
M. Cagnard,
D. Camus,
G. Colombet,
A. Debrabant,
J.-F. Dubremetz,
N. Dubreuil,
G. Prensier,
B. Fortier,
A. Haq,
J. Weber, and A. Vernes.
1988.
Protein p126: parasitophorous vacuole antigen associated with the release of Plasmodium falciparum merozoites.
Biol. Cell
64:215-221[Medline].
|
| 9.
|
Eakin, A. E.,
J. N. Higaki,
J. H. McKerrow, and C. S. Craik.
1989.
Cysteine or serine proteinase?
Nature
342:132[Medline].
|
| 10.
|
Fox, B. A.,
X.-L. Pang,
K. Suzue,
T. Horii, and D. J. Bzik.
1997.
Plasmodium falciparum: an epitope within a highly conserved region of the 47-kDa amino-terminal domain of the serine repeat antigen is a target of parasite-inhibitory antibodies.
Exp. Parasitol.
85:121-134[Medline].
|
| 11.
|
Gardner, M. L.,
H. Tetteelin,
D. J. Carucci,
L. M. Cummings,
L. Aravind,
E. V. Koonin,
S. Shallom,
T. Mason,
K. Yu,
C. Fujii,
J. Pederson,
K. Shen,
J. Jing,
C. Aston,
Z. Lai,
D. C. Schwartz,
M. Pertea,
S. Salzberg,
L. Zhou,
G. G. Sutton,
R. Clayton,
O. White,
H. O. Smith,
C. M. Fraser,
M. D. Adams,
J. C. Venter, and S. L. Hoffman.
1998.
Chromosome 2 sequence of the human malaria parasite Plasmodium falciparum.
Science
282:1126-1132[Abstract/Free Full Text].
|
| 12.
|
Higgins, D. G.,
D. J. McConnell, and P. M. Sharp.
1989.
Malaria proteinase?
Nature
340:604[Medline].
|
| 13.
|
Horii, T.,
D. J. Bzik, and J. Inselburg.
1988.
Characterization of antigen-expressing Plasmodium falciparum cDNA clones that are reactive with parasite inhibitory antibodies.
Mol. Biochem. Parasitol.
30:9-18[Medline].
|
| 14.
|
Inselburg, J.,
D. J. Bzik,
W.-B. Li,
K. M. Green,
J. Kansopon,
B. K. Hahm,
I. C. Bathurst,
P. J. Barr, and R. N. Rossan.
1991.
Protective immunity induced in Aotus monkeys by recombinant SERA proteins of Plasmodium falciparum.
Infect. Immun.
59:1247-1250[Abstract/Free Full Text].
|
| 15.
|
Inselburg, J.,
I. C. Bathurst,
J. Kansopon,
G. L. Barchfeld,
P. J. Barr, and R. N. Rossan.
1993.
Protective immunity induced in Aotus monkeys by a recombinant SERA protein of Plasmodium falciparum: adjuvant effects on induction of protective immunity.
Infect. Immun.
61:2041-2047[Abstract/Free Full Text].
|
| 16.
|
Inselburg, J.,
I. C. Bathurst,
J. Kansopon,
P. J. Barr, and R. Rossan.
1993.
Protective immunity induced in Aotus monkeys by a recombinant SERA protein of Plasmodium falciparum: further studies using SERA1 and MF75.2 adjuvant.
Infect. Immun.
61:2048-2052[Abstract/Free Full Text].
|
| 17.
|
Knapp, B.,
E. Hundt,
U. Nau, and H. A. Küper.
1989.
Molecular cloning, genomic structure and localization in a blood stage antigen of Plasmodium falciparum characterized by a serine stretch.
Mol. Biochem. Parasitol.
32:73-84[Medline].
|
| 18.
|
Kwiatkowski, D., and K. Marsh.
1997.
Development of a malaria vaccine.
Lancet
350:1696-1701[Medline].
|
| 19.
|
Lyon, J. A.,
J. D. Haynes,
C. L. Diggs,
J. D. Chulay, and J. M. Pratt-Rossiter.
1986.
Plasmodium falciparum antigens synthesized by schizonts and stabilized at the merozoite surface by antibodies when schizonts mature in the presence of growth inhibitory immune serum.
J. Immunol.
136:2252-2258[Abstract].
|
| 20.
|
Lyon, J. A.,
A. W. Thomas,
T. Hall, and J. D. Chulay.
1989.
Specificities of antibodies that inhibit merozoite dispersal from malaria-infected erythrocytes.
Mol. Biochem. Parasitol.
36:77-86[Medline].
|
| 21.
|
Miller, L. H.,
M. Aikawa, and J. A. Dvorak.
1975.
Malaria (Plasmodium knowlesi) merozoites: immunity and the surface coat.
J. Immunol.
114:1237-1242[Abstract/Free Full Text].
|
| 22.
|
Morimatsu, K.,
T. Morikawa,
K. Tanabe,
D. J. Bzik, and T. Horii.
1997.
Sequence diversity in the amino-terminal 47 kDa fragment of the Plasmodium falciparum serine repeat antigen.
Mol. Biochem. Parasitol.
86:249-254[Medline].
|
| 23.
|
Mrema, J. K. E.,
S. G. Langreth,
R. C. Jost,
K. H. Rieckmann, and H.-G. Heidrich.
1982.
Plasmodium falciparum: isolation and purification of spontaneously released merozoites by nylon membrane sieves.
Exp. Parasitol.
54:285-295[Medline].
|
| 23a.
| Pang, X.-L., M. Torii, and T. Horii.
Unpublished data.
|
| 24.
|
Pang, X.-L., and T. Horii.
1998.
Complement-mediated killing of Plasmodium falciparum erythrocytic schizont with antibodies to the recombinant serine repeat antigen (SERA).
Vaccine
16:1299-1305[Medline].
|
| 25.
|
Perkins, M. E., and A. Ziefer.
1994.
Preferential binding of Plasmodium falciparum SERA and rhoptry protein to erythrocyte membrane inner leaflet phospholipids.
Infect. Immun.
62:1207-1212[Abstract/Free Full Text].
|
| 26.
|
Sugiyama, T.,
K. Suzue,
M. Okamoto,
J. Inselburg,
K. Tai, and T. Horii.
1996.
Production of recombinant SERA protein of Plasmodium falciparum in Escherichia coli by using synthetic genes.
Vaccine
14:1069-1076[Medline].
|
| 27.
|
Suzue, K.,
M. Ito,
Y. Matsumoto,
Y. Tanioka, and T. Horii.
1997.
Protective immunity induced in squirrel monkeys with recombinant serine repeat antigen (SERA) of Plasmodium falciparum.
Parasitol. Int.
46:17-25.
|
| 28.
|
Tosta, C. E.,
M. Sedegah,
D. C. Henderson, and N. Wedderburn.
1980.
Plasmodium yoelii and Plasmodium berghei: isolation of infected erythrocytes from blood by colloidal silica gradient centrifugation.
Exp. Parasitol.
50:7-15[Medline].
|
| 29.
|
Trager, W., and J. B. Jensen.
1976.
Human malaria parasites in continuous culture.
Science
193:673-675[Abstract/Free Full Text].
|
| 30.
|
Trager, W., and H. N. Lanners.
1984.
Initial extracellular development in vitro of merozoites of Plasmodium falciparum.
J. Protozool.
31:562-567[Medline].
|
Infection and Immunity, April 1999, p. 1821-1827, Vol. 67, No. 4
0019-9567/99/$04.00+0
Copyright © 1999, American Society for Microbiology. All rights reserved.
This article has been cited by other articles:
-
Fairlie, W. D., Spurck, T. P., McCoubrie, J. E., Gilson, P. R., Miller, S. K., McFadden, G. I., Malby, R., Crabb, B. S., Hodder, A. N.
(2008). Inhibition of Malaria Parasite Development by a Cyclic Peptide That Targets the Vital Parasite Protein SERA5. Infect. Immun.
76: 4332-4344
[Abstract]
[Full Text]
-
Wang, L., Toda, M., Saito, K., Hori, T., Horii, T., Shiku, H., Kuribayashi, K., Kato, T.
(2008). Post-immune UV irradiation induces Tr1-like regulatory T cells that suppress humoral immune responses. Int Immunol
20: 57-70
[Abstract]
[Full Text]
-
McCoubrie, J. E., Miller, S. K., Sargeant, T., Good, R. T., Hodder, A. N., Speed, T. P., de Koning-Ward, T. F., Crabb, B. S.
(2007). Evidence for a Common Role for the Serine-Type Plasmodium falciparum Serine Repeat Antigen Proteases: Implications for Vaccine and Drug Design. Infect. Immun.
75: 5565-5574
[Abstract]
[Full Text]
-
Cheng, X.-J., Hayasaka, H., Watanabe, K., Tao, Y.-L., Liu, J.-Y., Tsukamoto, H., Horii, T., Tanabe, K., Tachibana, H.
(2007). Production of High-Affinity Human Monoclonal Antibody Fab Fragments to the 19-Kilodalton C-Terminal Merozoite Surface Protein 1 of Plasmodium falciparum. Infect. Immun.
75: 3614-3620
[Abstract]
[Full Text]
-
BERGMANN-LEITNER, E. S., DUNCAN, E. H., MULLEN, G. E., BURGE, J. R., KHAN, F., LONG, C. A., ANGOV, E., LYON, J. A.
(2006). Critical evaluation of different methods for measuring the functional activity of antibodies against malaria blood stage antigens.. Am J Trop Med Hyg
75: 437-442
[Abstract]
[Full Text]
-
OKECH, B., MUJUZI, G., OGWAL, A., SHIRAI, H., HORII, T., EGWANG, T. G.
(2006). HIGH TITERS OF IgG ANTIBODIES AGAINST PLASMODIUM FALCIPARUM SERINE REPEAT ANTIGEN 5 (SERA5) ARE ASSOCIATED WITH PROTECTION AGAINST SEVERE MALARIA IN UGANDAN CHILDREN. Am J Trop Med Hyg
74: 191-197
[Abstract]
[Full Text]
-
Lalitha, P. V., Ware, L. A., Barbosa, A., Dutta, S., Moch, J. K., Haynes, J. D., Fileta, B. B., White, C. E., Lanar, D. E.
(2004). Production of the Subdomains of the Plasmodium falciparum Apical Membrane Antigen 1 Ectodomain and Analysis of the Immune Response. Infect. Immun.
72: 4464-4470
[Abstract]
[Full Text]
-
Palacpac, N. M. Q., Hiramine, Y., Mi-ichi, F., Torii, M., Kita, K., Hiramatsu, R., Horii, T., Mitamura, T.
(2004). Developmental-stage-specific triacylglycerol biosynthesis, degradation and trafficking as lipid bodies in Plasmodium falciparum-infected erythrocytes. J. Cell Sci.
117: 1469-1480
[Abstract]
[Full Text]
-
Hodder, A. N., Drew, D. R., Epa, V. C., Delorenzi, M., Bourgon, R., Miller, S. K., Moritz, R. L., Frecklington, D. F., Simpson, R. J., Speed, T. P., Pike, R. N., Crabb, B. S.
(2003). Enzymic, Phylogenetic, and Structural Characterization of the Unusual Papain-like Protease Domain of Plasmodium falciparum SERA5. J. Biol. Chem.
278: 48169-48177
[Abstract]
[Full Text]
-
Soe, S., Singh, S., Camus, D., Horii, T., Druilhe, P.
(2002). Plasmodium falciparum Serine Repeat Protein, a New Target of Monocyte-Dependent Antibody-Mediated Parasite Killing. Infect. Immun.
70: 7182-7184
[Abstract]
[Full Text]
-
Miller, S. K., Good, R. T., Drew, D. R., Delorenzi, M., Sanders, P. R., Hodder, A. N., Speed, T. P., Cowman, A. F., de Koning-Ward, T. F., Crabb, B. S.
(2002). A Subset of Plasmodium falciparum SERA Genes Are Expressed and Appear to Play an Important Role in the Erythrocytic Cycle. J. Biol. Chem.
277: 47524-47532
[Abstract]
[Full Text]
-
Aoki, S., Li, J., Itagaki, S., Okech, B. A., Egwang, T. G., Matsuoka, H., Palacpac, N. M. Q., Mitamura, T., Horii, T.
(2002). Serine Repeat Antigen (SERA5) Is Predominantly Expressed among the SERA Multigene Family of Plasmodium falciparum, and the Acquired Antibody Titers Correlate with Serum Inhibition of the Parasite Growth. J. Biol. Chem.
277: 47533-47540
[Abstract]
[Full Text]
-
Hodder, A. N., Crewther, P. E., Anders, R. F.
(2001). Specificity of the Protective Antibody Response to Apical Membrane Antigen 1. Infect. Immun.
69: 3286-3294
[Abstract]
[Full Text]
-
Belperron, A. A., Feltquate, D., Fox, B. A., Horii, T., Bzik, D. J.
(1999). Immune Responses Induced by Gene Gun or Intramuscular Injection of DNA Vaccines That Express Immunogenic Regions of the Serine Repeat Antigen from Plasmodium falciparum. Infect. Immun.
67: 5163-5169
[Abstract]
[Full Text]